Medicine has been trying to keep people awake for as long as it has been trying to put them to sleep. From coca leaves chewed on Andean trails to the tightly regulated eugeroics prescribed in modern sleep clinics, the search for a reliable, safe way to fight drowsiness runs through centuries of pharmacology. Understanding that arc helps explain why today’s drugs look the way they do, why regulators treat them the way they do, and why the term wakefulness-promoting agent was coined at all rather than simply calling these compounds “stimulants.”
This article walks through that history: the plant-based beginnings, the amphetamine era, the discovery of modafinil in France, its arrival in the United States, and the branching out into armodafinil and beyond. Along the way you’ll see how each generation of drugs tried to fix the problems of the one before it.
Plants, Caffeine, and the Pre-Pharmaceutical Era
Long before anyone synthesized a molecule, people relied on plants. Tea in China, coffee in the Arabian Peninsula and Ethiopia, kola nut in West Africa, yerba mate in South America, and khat in the Horn of Africa all delivered alkaloids that pushed back fatigue. Caffeine, isolated in 1819 by the German chemist Friedlieb Ferdinand Runge, became the first purified wakefulness compound and remains the most widely consumed psychoactive substance on the planet.
Caffeine works mainly by blocking adenosine receptors. Adenosine accumulates in the brain during waking hours and builds “sleep pressure”; caffeine masks that signal without removing it. This is why the effect wears off relatively quickly and why tolerance builds. It was an effective tool, but physicians treating conditions like narcolepsy, first formally described by Jean-Baptiste-Édouard Gélineau in 1880, needed something stronger and more durable.
The Amphetamine Era
In 1887 the Romanian chemist Lazăr Edeleanu synthesized amphetamine, though its stimulant properties went unrecognized for decades. Ephedrine, extracted from the Chinese herb ma huang, was used in the 1920s for asthma and was noticed to increase alertness. Gordon Alles investigated amphetamine as an ephedrine substitute in the late 1920s, and by the mid-1930s Smith, Kline & French was selling Benzedrine, first as an inhaler for congestion and soon after in tablet form.
Amphetamine was quickly adopted for narcolepsy, and it genuinely worked. It also found its way into military use during World War II on nearly every side of the conflict, into dieting, into depression treatment, and eventually into widespread recreational use. Methylphenidate (Ritalin) followed in the 1950s, offering a somewhat gentler profile.
The problem was the mechanism. Amphetamines force dopamine and norepinephrine release from nerve terminals, which produces euphoria, tolerance, dependence, cardiovascular strain, and a hard crash. By the 1960s and 1970s, governments were tightening controls, and the medical world was looking for a way to promote wakefulness without the whole-body stimulant package.
Why “Stimulant” Became a Problematic Label
The word “stimulant” grouped together very different compounds. Caffeine, nicotine, cocaine, and amphetamine all stimulate, but by different routes and with different consequences. Researchers wanted a category for drugs that specifically increased wakefulness with minimal effect on mood, heart rate, and reward pathways. That category didn’t exist yet. The drug that would define it was being developed in a laboratory outside Paris.
The French Discovery: Adrafinil and Modafinil
In the 1970s, chemists at Laboratoire Louis Lafon in France were exploring a series of benzhydryl sulfinyl compounds. One of them, adrafinil, showed an unusual profile in animal testing: it increased locomotor activity and wakefulness without the stereotyped hyperactivity typical of amphetamine. Michel Jouvet, a pioneering French sleep researcher, became interested in the compound and helped characterize its effects on sleep architecture.
Adrafinil was launched in France in the 1980s under the name Olmifon, marketed primarily to elderly patients experiencing low energy and reduced attention. It worked, but slowly. Researchers soon realized why: adrafinil is a prodrug, meaning it is not active itself but is converted in the liver into an active metabolite. That metabolite was modafinil.
Modafinil turned out to be the better drug. It skipped the liver conversion step, so it acted faster and more predictably, and it avoided the liver-enzyme elevations that showed up with long-term adrafinil use. Lafon developed modafinil directly, and it was approved in France in 1994 under the brand name Modiodal for narcolepsy.
If you are curious how these compounds compare in practice today, a good place to start is a supplier that lists the modern options side by side; you can read about each wakefulness-promoting agent and its typical uses before deciding whether to raise the topic with your physician.
Crossing the Atlantic: Provigil and the FDA
Cephalon, a Pennsylvania biotech company, licensed modafinil for the US market and eventually acquired Lafon outright in 2001. The FDA approved modafinil as Provigil in December 1998 for excessive daytime sleepiness associated with narcolepsy. That approval marked a turning point. For the first time, American physicians had a drug that could treat pathological sleepiness without reaching for a Schedule II amphetamine.
The DEA placed modafinil in Schedule IV, reflecting its comparatively low abuse potential. In 2003 and 2004 the FDA expanded the label to include sleepiness due to obstructive sleep apnea (as an adjunct to treatment of the underlying airway problem) and shift work sleep disorder. Those three indications, narcolepsy, OSA-related sleepiness, and shift work disorder, remain the core approved uses.
The typical dose settled at 200 mg taken once in the morning, with 100 mg used in some patients and a half-life of roughly 12 to 15 hours, long enough to cover a workday without a mid-afternoon second dose.
The Marketing Controversy
Cephalon’s promotion of Provigil for uses beyond its approved indications, including fatigue in multiple sclerosis and depression, led to a federal investigation and a 2008 settlement of more than $400 million for off-label marketing. It was a reminder that a drug’s medical promise and its commercial promotion don’t always stay in step, and it shaped how cautiously later eugeroics were marketed.
Splitting the Molecule: Armodafinil
Modafinil is a racemic mixture, meaning it contains two mirror-image forms of the same molecule. Pharmacologists noticed that the R-enantiomer had a longer half-life and accounted for most of the drug’s activity later in the day. Cephalon isolated it, named it armodafinil, and won FDA approval in 2007 under the brand name Nuvigil for the same three indications.
Armodafinil is dosed at 150 to 250 mg once daily and has a half-life of about 15 hours. Many patients report that it feels slightly “cleaner” or longer-lasting than modafinil, though head-to-head studies show broadly similar efficacy. From a business standpoint, armodafinil also gave Cephalon a patent-protected product as generic modafinil entered the market in 2012.
How the Mechanism Was Finally Understood
For years, the way modafinil worked was frankly unclear. Early hypotheses pointed to adrenergic receptors, then to orexin (hypocretin) neurons, then to histamine. It took imaging and binding studies in the 2000s to establish that modafinil binds the dopamine transporter and inhibits dopamine reuptake, though far more weakly than cocaine or methylphenidate. Downstream, it increases activity in orexin and histamine systems that support arousal.
The clinical picture makes sense in that light: enough dopaminergic activity to promote wakefulness and some attention benefit, but not the flood of release that produces amphetamine-style euphoria and dependence. That profile is what earned it the label eugeroic, from the Greek for “good arousal.”
A Timeline of Key Milestones
| Year | Event |
| 1819 | Caffeine isolated by Runge |
| 1880 | Narcolepsy described by Gélineau |
| 1887 | Amphetamine first synthesized |
| 1935 | Benzedrine tablets marketed; amphetamine used for narcolepsy |
| 1970s | Lafon develops adrafinil and identifies modafinil |
| 1986 | Adrafinil (Olmifon) on the French market |
| 1994 | Modafinil approved in France as Modiodal |
| 1998 | FDA approves Provigil for narcolepsy |
| 2003–2004 | Label expanded to OSA and shift work disorder |
| 2007 | Armodafinil (Nuvigil) approved |
| 2011 | Adrafinil discontinued by Cephalon |
| 2012 | Generic modafinil enters the US market |
Beyond Medicine: Military, Academia, and the Enhancement Debate
Modafinil quickly attracted interest outside the clinic. Air forces in several countries studied it as an alternative to amphetamine for long missions, and it became a documented “go pill” option for pilots. Researchers looked at it for astronauts, surgeons on long shifts, and emergency responders.
At the same time, healthy students and professionals began using it as a cognitive enhancer, sparking a bioethics conversation that continues today. A well-cited 2015 systematic review in European Neuropsychopharmacology concluded that modafinil produces modest benefits in attention, executive function, and learning in healthy, non-sleep-deprived adults, with a favorable side-effect profile in the short term. That review reshaped the conversation from “does it work?” to “should healthy people use it, and under what rules?”
For anyone considering that question, the responsible path is still to talk to a doctor: prescription rules vary considerably by country, and no eugeroic replaces actual sleep. The drug can mask fatigue, but it cannot repair the memory consolidation and metabolic cleanup that only sleep provides.
Where the Field Is Heading
Research on wakefulness has moved toward the orexin system itself. Orexin receptor antagonists are now approved for insomnia, and orexin agonists are in development for narcolepsy type 1, where orexin-producing neurons are lost. Pitolisant, a histamine H3 receptor inverse agonist, was approved in the US in 2019 as the first non-controlled drug for narcolepsy, and solriamfetol, a dopamine-norepinephrine reuptake inhibitor, followed the same year.
None of these has displaced modafinil for general use. Its combination of long track record, generic pricing, and manageable side effects keeps it the default first-line choice. Modern sourcing has also become easier; a reputable supplier can tell you the difference between a branded and generic smart drug and what quality standards to expect, which matters more than ever now that the compounds are manufactured worldwide.
FAQ
Who invented modafinil? It emerged from research at Laboratoire Louis Lafon in France during the 1970s, where chemists working on benzhydryl sulfinyl compounds first developed adrafinil and then identified modafinil as its active metabolite. Michel Jouvet contributed important early work on its effects on sleep.
Why was adrafinil discontinued? Cephalon discontinued adrafinil in 2011. It was largely redundant once modafinil was available: it acted more slowly, required liver conversion, and carried concerns about elevated liver enzymes with chronic use. It was never approved in the United States.
Is modafinil a stimulant or a eugeroic? Both terms are used, but “eugeroic” is more precise. It signals that the drug promotes wakefulness through a mechanism, chiefly dopamine transporter inhibition with downstream orexin and histamine effects, that produces less euphoria and dependence than classical amphetamines.
What is the difference between modafinil and armodafinil? Modafinil is a mixture of two mirror-image molecules; armodafinil is only the longer-acting R-enantiomer. Armodafinil is dosed at 150 to 250 mg versus 100 to 200 mg for modafinil, and its effects tend to last slightly longer into the day.
Are eugeroics controlled substances? In the United States, modafinil and armodafinil are Schedule IV, the same tier as many sleep aids and benzodiazepines. Regulations differ elsewhere; some countries require a prescription but do not schedule them, and others restrict them more tightly.
Final Thoughts
The history of wakefulness-promoting agents is really a history of trying to separate alertness from everything that used to come with it: the jitters, the crash, the addiction. Caffeine gave us a gentle nudge, amphetamines gave us a sledgehammer, and modafinil gave us something in between that physicians could prescribe with less worry. Armodafinil refined that, and the newer orexin- and histamine-targeting drugs may refine it further. If you take one lesson from this timeline, let it be that every advance came from understanding mechanism a little better, and that the same care, knowing what a compound does and why, should guide anyone thinking about using one.
For more topic guides and related resources, visit Modavance.
